Daniel Aletaha

58.3k total citations · 11 hit papers
327 papers, 21.2k citations indexed

About

Daniel Aletaha is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Daniel Aletaha has authored 327 papers receiving a total of 21.2k indexed citations (citations by other indexed papers that have themselves been cited), including 268 papers in Rheumatology, 89 papers in Hematology and 73 papers in Immunology. Recurrent topics in Daniel Aletaha's work include Rheumatoid Arthritis Research and Therapies (246 papers), Systemic Lupus Erythematosus Research (105 papers) and Autoimmune and Inflammatory Disorders Research (78 papers). Daniel Aletaha is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (246 papers), Systemic Lupus Erythematosus Research (105 papers) and Autoimmune and Inflammatory Disorders Research (78 papers). Daniel Aletaha collaborates with scholars based in Austria, United States and United Kingdom. Daniel Aletaha's co-authors include Josef S Smolen, Josef S Smolen, Iain B. McInnes, Josef S Smolen, Paul Emery, Tanja Stamm, Klaus Machold, Helga Radner, Valerie Nell and Farideh Alasti and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

Daniel Aletaha

309 papers receiving 20.7k citations

Hit Papers

Rheumatoid arthritis 2005 2026 2012 2019 2016 2018 2018 2005 2007 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rheumatoid arthritis
    2016 3.4k citations Daniel Aletaha, Iain B. McInnes et al. profile →
  2. Rheumatoid arthritis
    2018 1.7k citations Josef S Smolen, Daniel Aletaha et al. profile →
  3. Diagnosis and Management of Rheumatoid Arthritis
    2018 1.5k citations Daniel Aletaha, Josef S Smolen profile →
  4. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
    2005 803 citations Daniel Aletaha, Tanja Stamm et al. profile →
  5. New therapies for treatment of rheumatoid arthritis
    2007 754 citations Josef S Smolen, Daniel Aletaha et al. profile →
  6. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.
    2006 661 citations Daniel Aletaha, Josef S Smolen profile →
  7. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
    2008 624 citations Maxime Dougados, Josef S Smolen et al. Annals of the Rheumatic Diseases profile →
  8. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
    2015 356 citations Daniel Aletaha et al. profile →
  9. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score
    2015 316 citations Monika Schoels, Daniel Aletaha et al. Annals of the Rheumatic Diseases profile →
  10. Distinctions Between Diagnostic and Classification Criteria?
    2015 299 citations Daniel Aletaha, Brian M. Feldman et al. profile →
  11. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
    2023 71 citations Andreas Kerschbaumer, Leonhard X. Heinz et al. Annals of the Rheumatic Diseases profile →

Peers

Daniel Aletaha
Comparison fields: 5 of 167
  • Rheumatology 15.0k
  • Hematology 5.4k
  • Immunology 4.7k
  • Molecular Biology 2.9k
  • Genetics 2.4k
Replace Piet L. C. M. van Riel with:
Piet L. C. M. van Riel Netherlands
Joel M. Kremer United States
Larry W. Moreland United States
Michael H. Weisman United States
Josef S Smolen Austria
Vibeke Strand United States
Ben A. C. Dijkmans Netherlands
Roy Fleischmann United States
Robert Landewé Netherlands
Ferdinand C. Breedveld Netherlands
Piet L. C. M. van Riel Netherlands View profile →
Citations per field, relative to Daniel Aletaha
Daniel Aletaha · 1×
Citations per year, relative to Daniel Aletaha
Daniel Aletaha · 1×

Countries citing papers authored by Daniel Aletaha

Since Specialization
Citations

This map shows the geographic impact of Daniel Aletaha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Aletaha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Aletaha more than expected).

Fields of papers citing papers by Daniel Aletaha

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Aletaha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Aletaha. The network helps show where Daniel Aletaha may publish in the future.

Co-authorship network of co-authors of Daniel Aletaha

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Aletaha. A scholar is included among the top collaborators of Daniel Aletaha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Aletaha. Daniel Aletaha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Development and validation of a Disease Activity index for PSoriatic Arthritis based on 44 joints (DAPSA44)
2025 ·Annals of the Rheumatic Diseases ·(unknown), Clementina López‐Medina, Désirée van der Heijde, Daniel Aletaha, Josef S Smolen, Anna Moltó, Sofía Ramiro
0
2
Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial
2024 ·RMD Open ·Johanna Elin Gehin, Rolf Anton Klaasen, Eirik Klami Kristianslund, (unknown), Joseph Sexton, David J. Warren, Daniel Aletaha, Espen A. Haavardsholm, Silje Watterdal Syversen, Guro Løvik Goll, Nils Bolstad
0
3
Association Between Achievement of Clinical Disease Control and Improvement in Patient‐Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT‐PsA 1 and 2 Randomized Controlled Trials
2024 ·ACR Open Rheumatology ·Arthur Kavanaugh, Philip J. Mease, Laure Gossec, Roberto Ranza, Shigeyoshi Tsuji, Kevin Douglas, Michael Lane, Ralph Lippe, Manish Mittal, Tianming Gao, Arathi R. Setty, (unknown), Daniel Aletaha, Peter Nash
2
4
The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination
2023 ·Frontiers in Medicine ·Selma Tobudic, Elisabeth Simader, (unknown), (unknown), Felix Kartnig, Leonhard X. Heinz, Péter Mandl, Helmuth Haslacher, Thomas Perkmann, Lisa Schneider, Thomas Nothnagl, Helga Radner, (unknown), Heinz Burgmann, Karin Stiasny, Gottfried Novacek, Walter Reinisch, Daniel Aletaha, Stefan Winkler, Stephan Blüml
5
5
Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses
2023 ·Rheumatology and Therapy ·Yoshiya Tanaka, Tsutomu Takeuchi, Tatsuya Atsumi, Bernard Combe, Daniel Aletaha, Toshihiko Kaise, (unknown)
2
6
OA06 Clinical outcomes of filgotinib in patients with rheumatoid arthritis aged ≥65 years: a post hoc subgroup analysis of Phase 2 and 3 clinical trials and ongoing long-term extensions
2023 ·Lara D. Veeken ·Maya H Buch, Bernard Combe, José A. Gómez‐Puerta, Roberto Caporali, Jacques‐Eric Gottenberg, (unknown), (unknown), (unknown), Katrien Van Beneden, Daniel Aletaha, Gerd R Burmester, René Westhovens, Yoshiya Tanaka
1
7
Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review
2023 ·Lara D. Veeken ·Elvis Hysa, Milena Bond, Lisa Ehlers, Dario Camellino, Louise Falzon, Christian Dejaco, Frank Buttgereit, Daniel Aletaha, Andreas Kerschbaumer
12
8
Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce
2023 ·RMD Open ·Gabriele De Marco, Alen Zabotti, Xenofon Baraliakos, Annamaria Iagnocco, Daniel Aletaha, (unknown), (unknown), Josef S Smolen, Dennis McGonagle, Laure Gossec
21
9
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022
2023 ·Annals of the Rheumatic Diseases ·Kevin Winthrop, John D. Isaacs, Philip J. Mease, Dimitrios T. Boumpas, Xenofon Baraliakos, Jacques‐Eric Gottenberg, Stefan Siebert, Marta Mosca, Neil Basu, Dana E. Orange, Rik Lories, Daniel Aletaha, Iain B. McInnes, T. Huizinga, Reinhard Voll, Ellen M. Gravallese, F C Breedveld, Josef S Smolen
15
10
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
2022 ·Annals of the Rheumatic Diseases ·Sytske Anne Bergstra, Alexandre Sepriano, Andreas Kerschbaumer, Désirée van der Heijde, Roberto Caporali, Christopher J Edwards, Patrick Verschueren, Savia de Souza, Janet Pope, Tsutomu Takeuchi, Kimme L Hyrich, Kevin Winthrop, Daniel Aletaha, Tanja Stamm, Jan W. Schoones, Josef S Smolen, Robert Landewé
56
11
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
2022 ·Annals of the Rheumatic Diseases ·Andreas Kerschbaumer, Alexandre Sepriano, Sytske Anne Bergstra, Josef S Smolen, Désirée van der Heijde, Roberto Caporali, Christopher J Edwards, Patrick Verschueren, Savia de Souza, Janet Pope, Tsutomu Takeuchi, Kimme L Hyrich, Kevin Winthrop, Daniel Aletaha, Tanja Stamm, Jan W. Schoones, Robert Landewé
90
12
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
2022 ·Annals of the Rheumatic Diseases ·Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, Josef S Smolen, Désirée van der Heijde, Roberto Caporali, Christopher J Edwards, Patrick Verschueren, Savia de Souza, Janet Pope, Tsutomu Takeuchi, Kimme L Hyrich, Kevin Winthrop, Daniel Aletaha, Tanja Stamm, Jan W. Schoones, Robert Landewé
80
13
Developing guidelines for ultrarare rheumatic disorders: a bumpy ride
2022 ·Annals of the Rheumatic Diseases ·David Piskin, Micol Romano, Daniel Aletaha, Brian M. Feldman, Raphaela Goldbach‐Mansky, Loreto Carmona, Erkan Demirkaya
4
14
Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis
2021 ·Rheumatology and Therapy ·Alen Zabotti, Orazio De Lucia, Garifallia Sakellariou, Alberto Batticciotto, Gilberto Cincinelli, Ivan Giovannini, Luca Idolazzi, Gabriella Maioli, Ilaria Tinazzi, Daniel Aletaha, Salvatore De Vita, Antonio Marchesoni, Josef S Smolen, Annamaria Iagnocco, Dennis McGonagle, Roberto Caporali
45
15
Side-by-Side Comparison of Three Fully Automated SARS-CoV-2 Antibody Assays with a Focus on Specificity
2020 ·Clinical Chemistry ·Thomas Perkmann, Nicole Perkmann‐Nagele, Marie‐Kathrin Breyer, Robab Breyer‐Kohansal, Otto C. Burghuber, Sylvia Hartl, Daniel Aletaha, Daniela Sieghart, Peter Quehenberger, Rodrig Marculescu, Patrick Mucher, Robert Straßl, Oswald Wagner, Christoph J. Binder, Helmuth Haslacher
80
16
Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider
2020 ·RMD Open ·Valentin Ritschl, Tanja Stamm, Daniel Aletaha, J. W. J. Bijlsma, Peter Böhm, Răzvan Drăgoi, Emma Dures, Fernando Estévez‐López, Laure Gossec, Annamaria Iagnocco, (unknown), Michal Nudel, Andréa Marques, (unknown), Conni Skrubbeltrang, Bart J. F. van den Bemt, Kirsten K. Viktil, Marieke Voshaar, Loreto Carmona, Annette de Thurah
23
17
2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice
2020 ·Annals of the Rheumatic Diseases ·Valentin Ritschl, Tanja Stamm, Daniel Aletaha, J. W. J. Bijlsma, Peter Böhm, Răzvan Drăgoi, Emma Dures, Fernando Estévez‐López, Laure Gossec, Annamaria Iagnocco, Andréa Marques, (unknown), Michal Nudel, Bart J. F. van den Bemt, Kirsten K. Viktil, Marieke Voshaar, Annette de Thurah, Loreto Carmona
34
18
Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?
2018 ·Annals of the Rheumatic Diseases ·Brigitte Michelsen, Joseph Sexton, Josef S Smolen, Daniel Aletaha, Niels Steen Krogh, Désirée van der Heijde, Tore K Kvien, Merete Lund Hetland
26
19
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update
2015 ·Annals of the Rheumatic Diseases ·Michaela Stoffer, Monika Schoels, Josef S Smolen, Daniel Aletaha, Ferdinand C. Breedveld, Gerd R Burmester, Vivian P. Bykerk, Maxime Dougados, Paul Emery, Boulos Haraoui, Juan J. Gómez‐Reino, Tore K Kvien, Peter Nash, Victoria Navarro‐Compán, Marieke Voshaar, Ronald van Vollenhoven, Désirée van der Heijde, Tanja Stamm
249
20
EULAR recommendations for the inclusion of patient representatives in scientific projects: A EULAR initiative
2011 ·UWE Research Repository (UWE Bristol) ·(unknown), (unknown), (unknown), Daniel Aletaha, (unknown), (unknown), (unknown), (unknown), Laure Gossec, Sandra Hewlett, Merryn Jongkees, Dawn Magnusson, Marieke Voshaar, Peter Richards, (unknown), Tineke Abma
3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Piet L. C. M. van Riel Breakdown of academic impact, for papers by Joel M. Kremer Breakdown of academic impact, for papers by Larry W. Moreland Breakdown of academic impact, for papers by Michael H. Weisman Breakdown of academic impact, for papers by Josef S Smolen Breakdown of academic impact, for papers by Vibeke Strand Breakdown of academic impact, for papers by Ben A. C. Dijkmans Breakdown of academic impact, for papers by Roy Fleischmann Breakdown of academic impact, for papers by Robert Landewé Breakdown of academic impact, for papers by Ferdinand C. Breedveld
Rankless by CCL
2026